Celcuity Inc.

Celcuity Inc. is a clinical-stage biotechnology company focused on developing targeted therapies for the treatment of various solid tumors. Its lead drug candidate is Gedatolisib, which selectively targets Class I isoforms of PI3K and the mTORC1 and mTORC2 sub-complexes. Gedatolisib is being developed for patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer, as well as for patients with metastatic castration resistant prostate cancer (mCRPC). The company operates in the United States and is headquartered in Minneapolis, Minnesota.

Celcuity Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol CELC. Its trading currency is the US Dollar (USD), as the company is based in the United States. The NasdaqCM is a US-based exchange that typically lists smaller-cap companies, and Celcuity's listing there reflects its status as a clinical-stage biotechnology firm.

Celcuity Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biotechnology company, it focuses on developing targeted therapies for solid tumors, particularly through its lead candidate Gedatolisib. Biotechnology companies like Celcuity engage in research and development of drugs, often with a focus on innovative treatments for diseases such as cancer.

Celcuity Inc. is headquartered in Minneapolis, Minnesota, United States. The company primarily serves the US market, as indicated by its country and region being the United States. Its clinical trials and development activities for Gedatolisib are focused on treating patients with advanced or metastatic breast cancer and metastatic castration resistant prostate cancer within the US. The company was incorporated in 2011 and has since been based in Minneapolis.

Celcuity's lead drug candidate is Gedatolisib, a targeted therapy that selectively inhibits various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. This dual inhibition is designed to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) advanced or metastatic breast cancer, and patients with metastatic castration resistant prostate cancer (mCRPC). Celcuity has a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib.